key: cord-0794798-gom8sh8v authors: Weinstock, Leonard B.; Brook, Jill B.; Walters, Arthur S.; Goris, Ashleigh; Afrin, Lawrence B.; Molderings, Gerhard J. title: Mast cell activation symptoms are prevalent in Long-COVID date: 2021-09-23 journal: Int J Infect Dis DOI: 10.1016/j.ijid.2021.09.043 sha: 831bed7b0578eb4b9e69454b528f929a511a5586 doc_id: 794798 cord_uid: gom8sh8v Objectives Hyper-inflammation caused by COVID-19 may be mediated by mast cell activation (MCA) which has also been hypothesized to cause Long-COVID (LC) symptoms. We determined prevalence/severity of MCA symptoms in LC. Methods Adults in LC-focused Facebook support groups were recruited for online assessment of symptoms before and after COVID-19. Questions included presence and severity of known MCA and LC symptoms and validated assessments of fatigue and quality of life. General population controls and mast cell activation syndrome (MCAS) patients were recruited for comparison if they were ≥18 years of age and never had overt COVID-19 symptoms. Results There were 136 LC subjects (89.7% females, age 46.9 ±12.9 years), 136 controls (65.4% females, age 49.2 ±15.5), and 80 MCAS patients (85.0% females, age 47.7 ±16.4). Pre-COVID-19 LC subjects and controls had virtually identical MCA symptom and severity analysis. Post-COVID-19 LC subjects and MCAS patients prior to treatment had virtually identical MCA symptom and severity analysis. Conclusions MCA symptoms were increased in LC and mimicked the symptoms and severity reported by patients who have MCAS. Increased activation of aberrant mast cells induced by SARS-CoV-2 infection by various mechanisms may underlie part of the pathophysiology of LC, possibly suggesting routes to effective therapy. The COVID-19 pandemic has spread throughout the world, with calamitous outcomes for some of those acutely infected and for those who struggle with Long- We examined the prevalence and severity of MCA symptoms in LC. The study was approved by the Missouri Baptist Medical Center Investigational questions for physical fatigue and 5 questions for mental fatigue. These ten FAS questions were ranked from 1 to 5: scores 10 to 21: no fatigue; scores 22 to 34: substantial fatigue; and scores: 35 to 50: extreme fatigue. The self-rated overall general health scores or QOL scores, were ranked on a scale from 0 to 100 where 0 was the worse imaginable health and the 100 was the best imaginable health. The LC subjects filled out their pre-COVID-19 questionnaire by recall; at the same time, they filled out their identical post-COVID-19 questionnaire. The MCAS patients were asked to answer the questionnaire by recall of their original symptoms and severity prior to treatment. The questions in the control and MCAS patient questionnaires were identical to the COVID-19 patients. The LC group filled out the two questionnaires which were titled: 1) INFECTION QUESTIONS (Appendix 1A and 1B). In this article, we designate the Long-COVID participants in the following manner: 1) pre-COVID-LC participants refers to the LC groups' characteristics and recall of symptoms prior to the acute infection with COVID-19; and 2) post-COVID-LC participants refers to the LC groups' current characteristics and symptoms in the LC state. The general population control group was composed of employees and their spouses from the Missouri Baptist Medical Center and the offices of the lead investigator (LBW). The MCAS patients were diagnosed in the last two years by the lead investigator and consented to filling out the questionnaire. The controls and the MCAS patients never had symptoms of an acute COVID-19 infection. The consent for the control group stated that they could volunteer even if they had chronic symptoms, conditions, or diseases. In this manner we did not exclude MCA symptoms in this group. The only other exclusion criteria for all groups were age <18 and current pregnancy (or pregnancy during COVID-19). General population control group was recruited through an Intranet posting and handouts advertising study (Appendix 2). The MCAS patients diagnosed in the last two years by the lead investigator were mailed a cover letter explaining the study and the consent form and questionnaires were enclosed in the packet (Appendix 3). The IRB committee gave their permission for these activities. The diagnosis of MCAS in the MCAS patient group was based on the following Consensus-2 diagnostic criteria, i.e., typical symptoms of MCA in 5 or more organ systems plus both of the following criteria: at least one or more elevated mast cell ( The MCMRS score also includes points for abnormal laboratory, radiographic, and biopsy findings, but these were not measured in the LC or general control group subjects. A score of ≥14 is consistent with a MC mediator release syndrome which is found in MCAS, mastocytosis, MC leukemia, and other disorders of MC activation (Appendix 4). The final requirement to diagnose MCAS was to exclude other appropriate disorders in the differential diagnosis. The questions in the MCMRS were used to construct the questionnaire that was administered to all 3 groups in the study. Additional questions were added to this that assessed known LC symptoms, FAS, and QOL (Appendix 1A and 1B). The MCMRS symptoms were assessed for LC participants and controls, but laboratory and biopsy findings were not measured. The MCMRS questionnaire was used in all subjects in three ways: total number of MCMRS symptoms, cumulative MCMRS severity scores which was the total of all symptom severity scores, and MCMRS system count which was the total number of body systems that were affected. The total number of MC and LC symptoms was also tabulated. The primary aims were to determine whether prevalence and severity of MCA symptoms in LC were: 1) starting from a baseline similar to healthy controls; 2) significantly higher after COVID-19; and 3) ultimately reaching a level that resembled MCAS patients. After scores were calculated for the MCMRS, each score and symptom underwent three analyses. First, independent samples t-tests or chi-square tests of independence compared LC group's pre-COVID-19 mean scores or symptom prevalence to those of controls. Second, paired samples t-tests or McNemar's tests were used to determine whether the LC group's mean scores or symptom prevalence were significantly higher after COVID-19. Third, independent samples t-tests or chisquare tests were again used to compare post-COVID scores/prevalence to those of MCAS patients prior to MCAS treatment. A value of p ≤ 0.05 was considered statistically significant. Finally, a spider web plot was created to better display mean MCMRS scores, with each spoke representing a system sub-score (e.g., lungs, heart, skin, etc.). The system sub-scores were normalized on a scale from 0 to 100%, to make each spoke the same length despite different maximum point values. Four spider web plots representing mean MCMRS scores were created, one each for general population controls, MCAS patients, pre-COVID-19 LC, and post-COVID-19 LC. All groups were queried as to a variety of medications and supplements. The LC group was also asked about medications and supplements used after COVID-19 infection. Medicines and supplements included: 1) those which could specifically affect the severity of acute COVID-19 (angiotensin converting enzyme inhibitors, carvedilol, and hydrochloroquine, five additional immune modulators and ten different biological agents); and 2) those that could reduce symptoms of MCA, MCAS, and/or COVID-19 (all anti-histamines including H2 blockers, aspirin, benzodiazepines, montelukast, nonsteroidal anti-inflammatory drugs, steroids, and vitamins C and D). Multivariant analysis was performed to determine if any clinical characteristic, medicine, or supplement altered the prevalence or severity of MCA symptoms in LC. Table 1 With this work-up and a careful history and physical examination, appropriate differential diagnoses were excluded. MCMRS scores were calculated for each participant and ranged from 0 to 34, with means shown in Figure 1 and Table 3 . Mean MCMRS scores for controls (9.7, SD Mean MCMRS scores were translated into spider web plots, with each spoke representing the mean score of symptoms affecting a different system (i.e., skin, abdomen, neurologic, etc.). Since each system had a different maximum possible score, they were normalized on a 0-100% scale to make each spoke the same length. The resulting MCMRS spider web plots are shown in Figure 3 . The MCMRS symptom count ranged from 0 to 35 among participants. As shown in Table 3 , mean pre-COVID-19 symptom count (11.6, SD 7.7) was not significantly different from that of controls [10. To further investigate potential similarities between post-COVID-19 symptoms and MCAS symptoms, the MCMRS cumulative severity score was calculated. Scores ranged from 0 to 466 among participants. As shown in Figure 2 and Table 3 Symptoms in the MCMRS were attributed to ten different bodily systems (lungs, skin, urinary/pelvic, etc.), and each participant's total number of affected systems was counted. Scores ranged from 0 to 10 among participants. As shown in Table 3 Individual symptoms -from the MCMRS and other common symptoms of MC activation or LC -were compared among the four groups. Symptom severity ratings ranged from 0 (not present) to 10 (most severe imaginable). For each of the 51 symptoms queried for severity, mean scores for pre-COVID-19 LC participants were first compared to those of controls using independent samples t-tests in order to determine whether baseline symptoms recalled by LC participants differed from those of controls. The first two columns of Table 4 show that baseline symptoms were not significantly different between pre-COVID-19 LC and controls for 48 of the 51 symptoms measured. There were significant differences for three symptoms: controls had more chest burning/pressure/pain, more brain fog, and less constipation than pre-COVID-19 LC participants. Next, repeated measures t-tests determined whether mean symptom severity scores increased in after COVID-19, as compared to before COVID-19. As shown in Table 4 , mean severity increased significantly for every symptom measured except seizures. To determine whether post-COVID-19 symptom severity resembled that reported by MCAS patients prior to MCAS treatment, independent samples t-tests were performed for each symptom. As shown in the last two columns of Table 4 , there were The occurrence of MCA symptoms in LC patients has previously not been examined in a detailed manner. In the present study, there was a high prevalence of MCA symptoms in LC patients prior to MCAS treatment. The symptom data and spiderweb plots illustrated that LC patients' symptoms are virtually identical to those were experienced within a 2-year period of the study and MCAS symptoms often are present for decades. Another potential problem is that the LC group completed their pre-COVID-19 questionnaire by recall, and thus this part of the study was retrospective. This was a limitation of the study design, yet the spider symptom/severity plots at baseline were remarkably similar to the general population control group, likely negating this issue. In this study, symptoms suggesting new MCA were significantly increased in LC. Changes in Long-COVID participants mean symptom severity scores before and after COVID-19 (all are statistically different; p<0.05). Often seen, rarely recognized: mast cell activation disease--a guide to diagnosis and therapeutic options. Review article Mast cell regulatory gene variants are common in mast cell activation syndrome Characterization of mast cell activation syndrome Covid-19 hyperinflammation and post-Covid-19 illness may be rooted in mast cell activation syndrome Mutational profiling in the peripheral blood leukocytes of patients with systemic mast cell activation syndrome using next-generation sequencing EuroQol-5D (EQ-5D): uno strumento per la misura della qualità della vita [EuroQol-5D (EQ-5D): an instrument for measuring quality of life Montelukast drug may improve COVID-19 prognosis: a review of evidence Naltrexone a potential therapeutic candidate for COVID-19 Quercetin and vitamin C: an experimental, synergistic therapy for the prevention and treatment of SARS-CoV-2 related disease (COVID-19) Assessment of fatigue among working people: a comparison of six questionnaires Long-term post-COVID symptoms and associated risk factors in previously hospitalized patients: A multicenter study Famotidine use is associated with improved clinical outcomes in hospitalized COVID-19 patients: a propensity score matched retrospective cohort study Sodium chromo-glycate and palmitoylethanolamide: A possible strategy to treat mast cell-induced lung inflammation in COVID-19 Systemic mast cell activation disease: the role of molecular genetic alterations in pathogenesis, heritability and diagnostics Evidence for contribution of epigenetic mechanisms in the pathogenesis of systemic mast cell activation disease The fatigue assessment scale: quality and availability in sarcoidosis and other diseases Dual-histamine receptor blockade with cetirizine -famotidine reduces pulmonary symptoms in COVID-19 patients Famotidine use and quantitative symptom tracking for COVID-19 in nonhospitalised patients: a case series Stabilizing mast cells by commonly used drugs: a novel therapeutic target to relieve post-COVID syndrome? COVID-19, mast cells, cytokine storm, psychological stress, and neuroinflammation Platelets and COVID-19: inflammation, hyperactivation and additional questions Mast cells contribute to coronavirus-induced inflammation: new anti-inflammatory strategy COVID-19 and autoimmune diseases Impact of famotidine use on clinical outcomes of hospitalized patients with COVID-19 Identification of key signaling pathways induced by SARS-CoV2 that underlie thrombosis and vascular injury in COVID-19 patients Die systemische Mastzellerkrankung mit gastrointestinal betonter Symptomatik--eine Checkliste als Diagnoseinstrument Von Kügelgen I. Multiple novel alterations in Kit tyrosine kinase in patients with gastrointestinally pronounced systemic mast cell activation disorder Comparative analysis of mutation of tyrosine kinase kit in mast cells from patients with systemic mast cell activation syndrome and healthy subjects Familial occurrence of systemic mast cell activation disease The genetic basis of mast cell activation disease -looking through a glass darkly Transgenerational transmission of systemic mast cell activation disease-genetic and epigenetic features Famotidine inhibits Toll-like receptor 3-mediated inflammatory signaling in SARS-CoV2 infection Risk factors for long-term consequences of COVID-19 in hospitalised adults in Moscow using the ISARIC Global follow-up protocol: StopCOVID cohort study Low level of vitamin C and dysregulation of vitamin C transporter might be involved in the severity of COVID-19 Infection COVID-19 as part of the hyperferritinemic syndromes: the role of iron depletion therapy Cytokine storm modulation in COVID-19: a proposed role for vitamin D and DPP-4 inhibitor combination therapy (VIDPP-4i) Borrelia burgdorferi spirochetes induce mast cell activation and cytokine release Recent advances in our understanding of mast cell activation -or should it be mast cell mediator disorders? COVID-19, pulmonary mast cells, cytokine storms, and beneficial actions of luteolin COVID-19 and multisystem inflammatory syndrome, or is it mast cell activation syndrome? Long-COVID syndromeassociated brain fog and chemofog: Luteolin to the rescue Potential association of mast cells with coronavirus disease 2019 Reaction of human monoclonal antibodies to SARS-CoV-2 proteins with tissue antigens: implications for autoimmune diseases The novel flavone tetramethoxyluteolin is a potent inhibitor of human mast cells Mast cell activation syndrome: a primer for the gastroenterologist Long COVID or post-COVID-19 syndrome: putative pathophysiology, risk factors, and treatments Low dose naltrexone and gut health Characterizing long Covid in an international cohort: 7 months of symptoms and their impact A detailed study of patients with long-haul COVID A 'mysterious' syndrome with 'no clear pattern' of symptoms We wish to thank Michael Brook who assisted in statistical analysis and preparation of the figures.